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Introduction 
Glioblastoma multiforme (GBM) is an aggressive brain 
tumor with no efficient treatment at present. We have de-
veloped a method to culture human GBM tissue obtained 
from surgery as organotypic slice cultures which allows 
for testing the effects of known treatment options includ-
ing X-irradiation or chemotherapy as well as applying 
novel compounds as well as Carbon ions [1, 2]. 
Method 
GBM tissue was transported to the lab and processed 
into organotypic slice cultures as described before . At 
different timepoints after treatments, slices were fixed, 
embedded, sectioned and used for morphological evalua-
tion (HE staining, Fig. 2) or analysis of proliferation or 
cell death with immunofluorescent stainings (Fig. 1). 
Results 
GBM slices were viable in culture for up to two weeks 
with preservation of general GBM hallmarks (protein 
expression, morphologic features) as well as the individu-
al characteristics of the initial tumor. When irradiated 
with X-rays or Carbon ions, a time-dependent decrease of 
proliferation in GBM slices was detected (Fig. 1 E and F). 
This was visualized by using an antibody against Ki-67 
which marks cells going through the cell cycle (Fig. 1 A-
D). 
 
Figure 1: Human GBM slice cultures were irradiated with X-
rays or Carbon ions and fixed after 6 or 24 hours. Staining with 
Ki-67 for proliferating cells revealed a significant decrease in 
proliferation after 24h. A and C= Control; B= Carbon irradiated 
(SOBP, 2 Gy); D= X-irradiated (4 Gy); E= proliferation index 6 
or 24h after Carbon; F= proliferation index 6 or 24h after X-rays 
When treated with the common chemotherapeutic drug 
temozolomide (TMZ) alone or in combination with irra-
diation, cell death was induced in slices. Morphological 
changes and cell loss were visible in HE stainings (Fig. 2 
A-D), and apoptosis induction was quantified by staining 
for activated caspase-3. In the tissues examined here, 
Carbon irradiation and TMZ induced more cell death and 
decreased cellular density (Fig. 2 E and F) than treatment 
with X-rays and TMZ (G and H). 
 
Figure 2: Human GBM slice cultures were treated with TMZ 
and Carbon ions (SOBP, 2 Gy) or X-rays (4 Gy). In HE stained 
sections, cell loss and morphological changes are visible (A-D). 
Fluorescent staining for activated caspase-3 and nuclei revealed 
induction of apoptosis and cell loss after treatment. The area 
covered by positive cells in at least 20 pictures per group was 
analyzed using ImageJ. 
The details of this study are now being published in 
Neuro-Oncology [3].  
Discussion 
Our model can be used to test effects of different 
known or novel therapeutic options in one tumor at a 
time. It can help exposing mechanisms of tumor re-
sistance and cell survival after treatment. In future, it 
could be used to identify the most suitable therapy strate-
gy for a patient before starting a treatment. 
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